These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. Lewin SR; Ribeiro RM; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini SA; Ruxrungtham K; Perelson AS; Dore GJ Hepatology; 2009 Apr; 49(4):1113-21. PubMed ID: 19115219 [TBL] [Abstract][Full Text] [Related]
4. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy. Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414 [TBL] [Abstract][Full Text] [Related]
5. Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV. Boyd A; Maylin S; Gozlan J; Delaugerre C; Simon F; Girard PM; Lacombe K Liver Int; 2015 Mar; 35(3):795-804. PubMed ID: 24606220 [TBL] [Abstract][Full Text] [Related]
6. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF; J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239 [TBL] [Abstract][Full Text] [Related]
7. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ Hepatology; 2008 Oct; 48(4):1062-9. PubMed ID: 18697216 [TBL] [Abstract][Full Text] [Related]
8. Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. Miailhes P; Maynard-Muet M; Lebossé F; Carrat F; Bouix C; Lascoux-Combe C; Sogni P; Rey D; Barthe Y; Pol S; Cacoub P; Zoulim F; Piroth L J Hepatol; 2014 Oct; 61(4):761-9. PubMed ID: 24882048 [TBL] [Abstract][Full Text] [Related]
9. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV. Zoutendijk R; Zaaijer HL; de Vries-Sluijs TE; Reijnders JG; Mulder JW; Kroon FP; Richter C; van der Eijk AA; Sonneveld MJ; Hansen BE; de Man RA; van der Ende ME; Janssen HL J Infect Dis; 2012 Sep; 206(6):974-80. PubMed ID: 22782950 [TBL] [Abstract][Full Text] [Related]
10. Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV. Wursthorn K; Buggisch P; Lutgehetmann M; Zollner B; Petersen J Antivir Ther; 2006; 11(5):647-52. PubMed ID: 16964835 [TBL] [Abstract][Full Text] [Related]
11. Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression. Huang AJ; Núñez M J Int Assoc Provid AIDS Care; 2015; 14(4):360-8. PubMed ID: 25999329 [TBL] [Abstract][Full Text] [Related]
12. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection. Gatanaga H; Hayashida T; Tanuma J; Oka S Clin Infect Dis; 2013 Jun; 56(12):1812-9. PubMed ID: 23487374 [TBL] [Abstract][Full Text] [Related]
14. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. Nebbia G; Garcia-Diaz A; Ayliffe U; Smith C; Dervisevic S; Johnson M; Gilson R; Tedder R; Geretti AM J Med Virol; 2007 Oct; 79(10):1464-71. PubMed ID: 17705185 [TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy. Hafkin JS; Osborn MK; Localio AR; Amorosa VK; Kostman JR; Stern JJ; De La Torre P; Mounzer K; Frank I; Gross R; Chang KM; Lo Re V J Viral Hepat; 2014 Apr; 21(4):288-96. PubMed ID: 24597697 [TBL] [Abstract][Full Text] [Related]
16. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients. Maylin S; Boyd A; Lavocat F; Gozlan J; Lascoux-Combe C; Miailhes P; Lassel L; Delaugerre C; Girard PM; Zoulim F; Lacombe K AIDS; 2012 May; 26(8):939-49. PubMed ID: 22333748 [TBL] [Abstract][Full Text] [Related]
17. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. Price H; Dunn D; Pillay D; Bani-Sadr F; de Vries-Sluijs T; Jain MK; Kuzushita N; Mauss S; Núñez M; Nüesch R; Peters M; Reiberger T; Stephan C; Tan L; Gilson R PLoS One; 2013; 8(7):e68152. PubMed ID: 23874527 [TBL] [Abstract][Full Text] [Related]
19. Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients. Boyd A; Canini L; Gozlan J; Lascoux-Combe C; Miailhes P; Fonquernie L; Girard PM; Lacombe K J Clin Virol; 2017 Oct; 95():55-60. PubMed ID: 28869890 [TBL] [Abstract][Full Text] [Related]
20. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]